The abstract is read at the publisher; the summary is JClub's.
After three COVID-19 vaccine doses, vaccine effectiveness against SARS-CoV-2 infection with pre-omicron variants was 82·3% (95% CI 72·4–88·7) in adults on immunosuppressive therapies.
- Why it matters: People receiving immunosuppressive therapies face higher risk of severe COVID-19, but trial evidence on vaccine effectiveness in these groups has been limited, leaving uncertainty for clinical decision-making.
- What they did: A systematic review and random-effects meta-analysis pooled 34 eligible studies (from 3316 identified) of adults with haematological malignancies or autoimmune/immune-mediated inflammatory disorders, using inverse-variance weighting and reporting heterogeneity with I².
- The result: Compared with vaccinated healthy controls, relative risks were 1·57 for infection, 3·72 for hospitalisation, and 3·14 for death, while vaccine effectiveness against hospitalisation was 88·4% (82·8–92·3).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.